Abstrato

Immune enhancement therapy in COVID-19 patients: A mini review.

Wen Fei*

In March 2020, when COVID sickness 2019 (COVID-19) was simply starting to spread all over the planet, we introduced the expected advantages and contentions of calming treatment in COVID-19 patients in view of the restricted insight and proposed a few kinds of mitigating drugs with likely remedial worth, while without proof based information. In another year, numerous clinical preliminaries or certifiable examinations have been performed, either verify or refute the viability of specific mitigating drugs in the treatment of COVID-19. In this audit we sum up the advancement of mitigating and resistant treatment in COVID-19, including glucocorticoids, IL-6 bad guy, IL-1 inhibitor, kinase inhibitors, non-steroidal calming medications and chloroquine/ hydroxychloroquine.